David Bearss Ph.D.

David Bearss Ph.D. is currently holding multiple positions in various companies including Halia Therapeutics, Biolexis Therapeutics, Inc., BioUtah, UVB Capital, University of Utah, Canary Speech, Systems Oncology, and Reglagene. With a background in Oncology and Cancer Biology, David has also served on the board of directors, as a partner, president, and senior managing director in different organizations. David holds a Ph.D. in Cell and Molecular Biology and a B.S. in Human Biology.